source
- Roche partners with China's Defand Therapeutics to discover molecular glue medicinesRoche announced a collaboration with Chinese biotech Defand Therapeutics aimed at discovering new molecular glue medicines for oncology and immune‑mediated diseases. Unlike typical licensing deals…
- Argenx halts Phase 3 Sjögren's trial as celiac disease data brings mixed resultsArgenx disclosed on Thursday that it is ending its Phase 3 trial in Sjögren's syndrome after the study failed to meet its primary endpoint. The decision came alongside the release of encouraging r…